SAB Biotherapeutics, Inc. (SABS)
| Market Cap | 248.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 4.26M |
| Shares Out | 70.28M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 234,315 |
| Open | 3.470 |
| Previous Close | 3.470 |
| Day's Range | 3.430 - 3.560 |
| 52-Week Range | 1.530 - 6.600 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 10.75 (+204.53%) |
| Earnings Date | May 12, 2026 |
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price target is $10.75, which is an increase of 204.53% from the latest price.
News
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-...
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE ...
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027
SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026
SAB-142, a human anti-thymocyte globulin, is in Phase IIb for newly diagnosed type 1 diabetes, showing strong efficacy and safety advantages over existing therapies. The pivotal SAFEGUARD trial is progressing well, with robust financial backing and plans for broader autoimmune indications.
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
SAB-142, a fully human anti-thymocyte globulin, is in a pivotal Phase IIb trial for newly diagnosed type 1 diabetes, aiming to preserve beta cells with a superior safety and dosing profile compared to existing therapies. Top-line data are expected in the second half of 2027, with a strong cash runway and significant market potential.
SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
SAB-142, a fully human anti-thymocyte immunoglobulin, is in a pivotal global trial for newly diagnosed Type 1 Diabetes, aiming to preserve beta cell function and enable chronic dosing without immunogenicity. Enrollment is set to finish by end of 2026, with data expected in 2027.
SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
SAB-142, a fully human anti-thymocyte immunoglobulin, is in a pivotal global phase II-B trial for type 1 diabetes, showing strong safety and redosing advantages over competitors. The company is fully funded through 2028 and aims for significant market impact and future label expansion.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D.
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:...
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing ...
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
A human anti-thymocyte immunoglobulin is advancing to a pivotal phase II-B trial for type 1 diabetes, aiming to offer durable efficacy without immunogenicity or lymphodepletion. Regulatory trends support C-peptide as an approval endpoint, and a significant commercial opportunity exists for this first-in-class therapy.
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
SAB-142, a human anti-thymocyte globulin, is advancing in a pivotal phase 2b trial for newly diagnosed type 1 diabetes, aiming to address safety and efficacy gaps left by Thymoglobulin. The FDA-endorsed Safeguard study targets a $5B+ market, with data expected in H2 2027.
SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025
A pivotal global phase 2b trial for a novel human IgG-based immunomodulator in type 1 diabetes is underway, targeting newly diagnosed patients and aiming for best-in-class efficacy and safety. The study is fully funded through 2028, with data expected in late 2027.
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
SAB BIO Highlights Data in Multiple Presentations at EASD
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in ...
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operati...
SAB BIO Announces Oversubscribed $175 Million Private Placement
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Scien...